Form 4: Precision BioSciences CFO John Alexander Kelly Reports Stock Vesting
SEC Form 4 Filing
John Alexander Kelly, CFO of Precision BioSciences, reports the vesting of restricted stock units.
Summary
- On November 2, 2024, John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, had 3,605 Restricted Stock Units (RSUs) vest.
- These RSUs represent a contingent right to receive one share of Precision BioSciences' Common Stock each.
- Following the transaction, Kelly directly owns 35,073 shares of common stock and 3,605 RSUs.
- The RSUs were granted on November 2, 2022, and vest in three substantially equal annual installments beginning on November 2, 2023, contingent upon continued service to the Issuer.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting scheduled vesting of compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity holdings of key personnel.
Key Dates
| Date | Description |
|---|---|
| 11/02/2022 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023 |
| 11/02/2023 | First vesting date of RSUs granted on November 2, 2022 |
| 11/02/2024 | Vesting of 3,605 Restricted Stock Units |
| 11/05/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.